Veru Inc. announced financial results for fiscal year 2025 and provided updates on the clinical progress of its obesity program.
Positive efficacy and safety results from the Phase 2b QUALITY study led to FDA regulatory clarity for enobosarm in combination with GLP-1 RA.
The company completed a public offering post fiscal year end for net proceeds of approximately $23.4 million.
FDA Regulatory Clarity for Enobosarm
Received FDA regulatory clarity for enobosarm in combination with GLP-1 RA post positive Phase 2b QUALITY study results.
Phase 2 PLATEAU Study
Company plans to initiate the Phase 2 PLATEAU clinical study in calendar Q1 2026 to address weight loss plateau challenges.
Public Offering Completion
Completed a public offering post fiscal year end, generating net proceeds of approximately $23.4 million.
Enobosarm for Obesity Treatment
Enobosarm, as a next-generation drug, aims to make weight loss more selective for fat while preserving lean mass and physical function.
- The Phase 2b QUALITY study demonstrated that enobosarm, in combination with GLP-1 RA, can effectively preserve lean mass while promoting fat loss, addressing a key challenge in obesity treatment.
- Enobosarm showed promising results in burning fat, preserving muscle, and enhancing physical function, potentially breaking through weight loss plateaus experienced by patients on GLP-1 RA therapy.
Veru's focus on developing innovative medicines for cardiometabolic and inflammatory diseases, showcased by the progress in their obesity program, positions them as a key player in the biopharmaceutical industry.